771 patents
Utility
Using Neural Networks to Predict Peptide Immunogenicity
18 Jan 24
Methods, systems, compositions, and computer program products are provided for accurately identifying candidate neoantigens that exhibit imnmunogenic properties.
Kai LIU, Milad SALEM, William John THRIFT
Filed: 22 Sep 23
Utility
ANTI-CD8 Antibodies and Uses Thereof
18 Jan 24
Provided are anti-CD8 antibodies that bind human CD8 and do not stimulate or inhibit the activation of CD8+ T cells.
Yvonne M. CHEN, Eugene Yu-Chuan CHIANG, Jane Louise GROGAN, Simon-Peter WILLIAMS, Matthew Lawrence ALBERT
Filed: 30 Jun 23
Utility
Defect Detection In Lyophilized Drug Products with Convolutional Neural Networks
18 Jan 24
In one embodiment, a method includes receiving one or more querying images associated with a container of a pharmaceutical product, each of the one or more querying images being based on a particular angle of the container of the pharmaceutical product, calculating one or more confidence scores associated with one or more defect indications, respectively for the container of the pharmaceutical product, by processing the one or more querying images using a target machine-learning model, and determining a defect indication for the container of the pharmaceutical product from the one or more defect indications based on a comparison between the one or more confidence scores and one or more predefined threshold scores, respectively.
Zheng LI, Calvin Tsay
Filed: 25 Sep 23
Utility
Process for the Preparation of a Chiral Triol
18 Jan 24
Anna-Lena GLASS, Allen Yu HONG, Kurt PUENTENER
Filed: 12 Jul 23
Utility
Dosing for Treatment with ANTI-FCRH5/ANTI-CD3 Bispecific Antibodies
18 Jan 24
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
Bernard Martin FINE, Teiko SUMIYOSHI, Mengsong LI, James Niall COOPER
Filed: 4 Apr 23
Utility
Methods for Preparing Mammalian Cells for Perfusion Cell Culture
11 Jan 24
Methods for preparing mammalian cells for perfusion cell culture processes that improve the growth and productivity of the cells are provided.
Ryan Christopher Hundley, Michael Wilson Laird, Jerome Joseph Bill, Christopher J. Dowd
Filed: 25 May 23
Utility
Production Cells
11 Jan 24
Herein are reported modified mammalian cells wherein the expression of the MYC gene and one or more of the BAK, BAX, SIRT-1 and ICAM-1 genes has been reduced or eliminated as well as methods for the recombinant production of a heterologous polypeptide using a modified mammalian cell according to the current invention.
Shahram Misaghi, Amy Shen, Inn Huam Yuk, Gavin Christian Barnard, Simon Auslaender, Niels Bauer, Benedikt Oswald
Filed: 19 Apr 23
Utility
Multiplexed Total Antibody and Antibody-conjugated Drug Quantification Assay
11 Jan 24
Methods are disclosed to detect, characterize, measure, and quantify human and humanized antibodies, and their conjugates, that may be present in pre-clinical animal biological samples, or human biological samples, including plasma/serum and tissue samples.
Surinder Kaur, Ola Saad, Manjui Violet Lee
Filed: 19 Sep 23
Utility
Diagnostic and Therapeutic Methods for Cancer
11 Jan 24
The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., a bladder cancer (e.g., UC, e.g., mUC), a kidney cancer, a lung cancer, a liver cancer, an ovarian cancer, a pancreatic cancer, a colorectal cancer, or a breast cancer).
Yinghui GUAN, Yasin SENBABAOGLU, Shannon TURLEY, Yulei WANG
Filed: 1 Sep 22
Utility
Methods and Systems for Raman Spectra-based Identification of Chemical Compounds
11 Jan 24
A method and System for identifying chemical compounds based on Raman spectroscopic measurements and in-silico simulated Raman spectra are disclosed.
Andrew James MAIER, Raphael FISH, Brendan Reed HUANG
Filed: 10 Aug 23
Utility
ANTI-PDL1 Antibody Formulations
11 Jan 24
The invention provides stable aqueous pharmaceutical formulations comprising an anti-PDL1 antibody.
Ying YANG, Sreedhara ALAVATTAM
Filed: 2 Aug 23
Utility
Methods for Modulating Host Cell Surface Interactions with Herpesviruses
11 Jan 24
Provided herein are methods of treating or preventing herpesvirus infection comprising modulating interactions between herpesvirus surface proteins and plasma membrane-expressed host cell proteins, as well as methods of identifying modulators of such interactions.
Nadia MARTINEZ-MARTIN, Bushra HUSAIN
Filed: 21 Aug 23
Utility
Inductive Heat Sterilizing Systems, Devices, and Methods
4 Jan 24
A system for making a sterile connection of at least one conduit is provided.
Luis Fernando Caldera, Arthi Narayanan, Trishna Ray-Chaudhuri, Nicholas Rummel
Filed: 31 May 23
Utility
Combination Therapy of a Type II ANTI-CD20 Antibody with a Selective BCL-2 Inhibitor
4 Jan 24
The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
Filed: 7 Sep 23
Utility
Systems, Apparatus, and Methods for Cell Culture
4 Jan 24
Embodiments described herein generally relate to assemblies, systems, and methods for cell culture and production of biologics.
Edward Hon Man CHAN, Rigzen Pratap Singh AULAKH, Dominik MARKS, Christian SCHANTZ
Filed: 29 Jun 23
Utility
Methods for Producing Antibodies
4 Jan 24
Provided herein are methods for the production and identification of antibodies that bind to a desired region of a target protein.
Wei-Ching LIANG, WeiYu LIN, Yan WU
Filed: 27 Feb 23
Utility
Treatment of Ophthalmologic Diseases
28 Dec 23
The current invention relates to the use of antibodies which bind to VEGF and ANG2 for the treatment of ophthalmologic diseases.
Aaron Osborne, Jayashree Sahni, Robert James Weikert
Filed: 9 Feb 23
Utility
Combination Treatment of an ANTI-CD20/ANTI-CD3 Bispecific Antibody and Chemotherapy
28 Dec 23
The present invention relates to methods of treating B-cell proliferative disorders, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering an anti-CD20/anti-CD3 bispecific antibody and in combination with an anti-CD20 antibody (e.g., obinutuzumab or rituximab) and one or more chemotherapeutic agents selected from ifosfamide, carboplatin, and/or etoposide.
Maria FILIPPOU-FRYE, Joseph Nathaniel PAULSON, Leonardo ROQUE PEREIRA, Emily PICCIONE GRIFFIN, Stephen James SIMKO, III, Johanna SY, Akiko TAGAWA, Beate WULFF, Betsy Lane ALTHAUS, David CARLILE, Nassim DJEBLI
Filed: 22 Mar 23
Utility
Composition Comprising Antibody That Binds to Domain II of HER2 and Acidic Variants Thereof
28 Dec 23
A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described.
Reed J. HARRIS, Paul MOTCHNIK
Filed: 9 Feb 23
Utility
Dosing for Treatment with ANTI-CD20/ANTI-CD3 Bispecific Antibodies In Elderly Patients
28 Dec 23
The present invention relates to the treatment of elderly subjects (e.g., subjects aged 65 years or older) having relapsed and/or refractory (R/R) non-Hodgkin's lymphoma (NHL).
Huang HUANG, Carol Elaine O'HEAR, Iris Tranthuyngan TO, Michael Ching-sun WEI, Shen YIN
Filed: 31 May 23